People · Operator
Named in public records as an officer, director or promoter · active 2010–2012 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Animal Cell Therapies, Inc. | — | Biotechnology | Series A | $10.1M | $202.0M | 2010 |
Stephen A. De Kanter at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Stephen A. De Kanter on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Gary M. Petrucci | 1 | 2 |
| Nikolai Tankovich | 1 | 2 |
| Roger Kuhn | 1 | 1 |
| Roger J. Kuhn | 1 | 1 |
| Nikolai M. Tankovich | 1 | 1 |
| Adam A. Irving | 1 | 1 |
| Roger C. Kuhn | 1 | 1 |
| Leo M. Furcht | 1 | 1 |
| Shaun M. Bishop | 1 | 1 |
| Steve M. Simon | 1 | 1 |
| Derek J. Howe | 1 | 1 |
| Dean M. Spatz | 1 | 1 |
| Kathryn J. Petrucci | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.